HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PLX
Protalix BioTherapeutics, Inc.
PLX's fundamentals are strong and it looks cheap: trading at 11x earnings, less than half its usual 26x. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PLX's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $2.96 | — |
| Cheap | 12x | $3.21 | +8.4% |
| Forward | 25x | $2.96 | — |
| Fair | 26x | $6.68 | +126% |
| Expensive | 43x | $11.27 | +281% |
Historical ranges are pointers, not guarantees.
PLX's PE is in its cheap range at 11x. On analysts' estimates for next year's earnings, today's price would be 25x, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PLX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PLX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.12 | -54% |
| Q3 2026 | $0.26 | +225% |
| Q2 2026 | $0.24 | +200% |
| Q1 2026 | $0.19 | +280% |
| Q4 2025 | -$0.08 | -300% |
| Q3 2025 | $0.08 | +$0.17 |
| Q2 2025 | $0.08 | +$0.24 |
| Q1 2025 | $0.05 | -38% |
| Q4 2024 | $0.04 | -56% |
PLX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PLX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.9M | +23% |
| Q2 2026 | $19.9M | +27% |
| Q1 2026 | $33.8M | +234% |
| Q4 2025 | $9.1M | -50% |
| Q3 2025 | $17.9M | -0.6% |
| Q2 2025 | $15.7M | +16% |
| Q1 2025 | $10.1M | +170% |
| Q4 2024 | $18.2M | +74% |
PLX's revenue is recovering but still below its 2023 peak: $22M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +6.5 points |
| Q2 2026 | 23% | +16 points |
| Q1 2026 | 63% | +104 points |
| Q4 2025 | -51% | -91 points |
| Q3 2025 | 12% | -10 points |
| Q2 2025 | 7.5% | +26 points |
| Q1 2025 | -41% | +89 points |
| Q4 2024 | 40% | +93 points |
PLX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PLX on cash flow, with more consistent year-over-year improvement.
PLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.2M | +$7.4M |
| Q2 2026 | -$11M | -$5.3M |
| Q1 2026 | $21.3M | +$26.6M |
| Q4 2025 | $1.6M | -54% |
| Q3 2025 | -$4.2M | -205% |
| Q2 2025 | -$5.7M | -$1.9M |
| Q1 2025 | -$5.4M | -249% |
| Q4 2024 | $3.6M | +6.6% |
PLX's free cash flow has turned positive again: $15M over the past year, against −$12M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1M shares |
| 1 year | +3.4% | +2.8M shares |
| 3 years | -0.2% | -196K shares |
| 5 years | +84% | +38.1M shares |
| Available history | +463% | +68.7M shares |
PLX has 84M diluted shares, up 3.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.9x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
| Q1 2024 | -2.9x | Net Cash |
PLX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.4 | Neutral |
| Stochastic | 65.9 | Neutral |
PLX's weekly RSI is 65 (neutral) and its Stochastic is 66 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PLX PE vs Healthcare Sector
| Metric | PLX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 56% below |
| PE % | 13 | 29 | 16 pts below |
PLX is trading at 11x earnings, a 56% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 10% above |
| 20 week MA | $2.55 | 16% above |
| 50 week MA | $2.35 | 26% above |
| 100 week MA | $2.18 | 36% above |
| 200 week MA | $1.87 | 58% above |
PLX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.79 | $3.44 | +23% |
| 2021 | $3.44 | $0.95 | -72% |
| 2022 | $0.95 | $1.18 | +24% |
| 2023 | $1.18 | $1.78 | +51% |
| 2024 | $1.78 | $1.83 | +2.8% |
| 2025 | $1.83 | $1.81 | -1.1% |
| 2026 YTD | $1.81 | $2.96 | +64% |
PLX has the edge over HIMS on returns for 2026, with the stronger performance.